Edition:
United Kingdom

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

2.76USD
6:46pm GMT
Change (% chg)

$-0.14 (-4.83%)
Prev Close
$2.90
Open
$2.94
Day's High
$2.94
Day's Low
$2.75
Volume
119,749
Avg. Vol
225,332
52-wk High
$5.97
52-wk Low
$2.75

Latest Key Developments (Source: Significant Developments)

Keryx Biopharmaceuticals Reports Q3 Loss Per Share Of $0.14
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.14.Q3 REVENUE $28 MILLION VERSUS I/B/E/S VIEW $29.1 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.KERYX BIOPHARMACEUTICALS - CASH AND CASH EQUIVALENTS AS OF SEPT 30, 2018 TOTALED $41.1 MILLION.KERYX BIOPHARMACEUTICALS - MERGER WITH AKEBIA THERAPEUTICS ON TRACK TO CLOSE BY YEAR END.  Full Article

Keryx Signs Letter Of Intent with Akebia Therapeutics Related To Auryxia
Thursday, 25 Oct 2018 

Oct 26 (Reuters) - Keryx Biopharmaceuticals ::ON OCT 24, ENTERED LETTER AGREEMENT WITH PANION & BF BIOTECH, AND AKEBIA THERAPEUTICS RELATED TO AURYXIA - SEC FILING.PANION AGREED TO RESCIND ANY AND ALL PRIOR TERMINATION THREATS OR NOTICES RELATING TO LICENSE AGREEMENT.PANION WAIVED ITS RIGHTS TO TERMINATE LICENSE AGREEMENT BASED ON ANY BREACH BY KERYX OF CERTAIN OBLIGATION.TERMS INCLUDE ESTABLISHING A JOINT STEERING COMMITTEE WITH PANION, AKEBIA REPRESENTATIVES RELATED TO FEXERIC IN EUROPE.  Full Article

Akebia Therapeutics And Keryx Biopharmaceuticals To Merge
Thursday, 28 Jun 2018 

June 28 (Reuters) - Akebia Therapeutics Inc ::AKEBIA THERAPEUTICS AND KERYX BIOPHARMACEUTICALS TO MERGE, CREATING A FULLY INTEGRATED COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF THERAPEUTICS FOR PATIENTS WITH KIDNEY DISEASE.SAYS IMPLIED PRO FORMA EQUITY VALUE OF COMBINED CO IS ABOUT $1.3 BILLION.SAYS KERYX SHAREHOLDERS WILL RECEIVE 0.37433 COMMON SHARES OF AKEBIA FOR EACH SHARE OF KERYX THEY OWN.SAYS JOHN P. BUTLER TO BE PRESIDENT AND CHIEF EXECUTIVE OFFICER OF COMBINED COMPANY; KERYX TO APPOINT CHAIRPERSON OF BOARD.SAYS COMBINED COMPANY WILL HAVE $453 MILLION IN CASH ON ITS BALANCE SHEET (UNAUDITED PRO FORMA CASH BALANCE AS OF MARCH 31, 2018).SAYS BOARD OF DIRECTORS OF COMBINED COMPANY EXPECTED TO CONSIST OF NINE DIRECTORS, FOUR FROM AKEBIA DIRECTORS, FOUR FROM KERYX DIRECTORS.SAYS BOARDS OF BOTH COMPANIES HAVE UNANIMOUSLY APPROVED, A DEFINITIVE MERGER UNDER WHICH COS WILL COMBINE IN AN ALL-STOCK MERGER.SAYS DEAL RESULTS IN IMPLIED EQUITY OWNERSHIP IN COMBINED CO OF 49.4 PERCENT FOR CO SHAREHOLDERS, 50.6 PERCENT FOR KERYX SHAREHOLDERS ON FULLY-DILUTED BASIS.SAYS JASON A. AMELLO, AKEBIA'S CFO, IS EXPECTED TO SERVE IN SAME CAPACITY ON MANAGEMENT TEAM OF COMBINED COMPANY.SAYS KERYX WILL APPOINT CHAIRPERSON OF BOARD OF DIRECTORS OF COMBINED COMPANY.SAYS EXPECTED COST SYNERGIES OF GREATER THAN $250 MILLION TO BE REALIZED FIVE YEARS FOLLOWING CLOSING OF DEAL.  Full Article

Keryx Biopharmaceuticals Reports Q1 Loss Per Share Of $0.18
Thursday, 10 May 2018 

May 10 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.18.Q1 REVENUE $21.7 MILLION VERSUS I/B/E/S VIEW $21.8 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018 TOTALED $60.1 MILLION.  Full Article

Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln
Monday, 30 Apr 2018 

April 30 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING.SAYS CEO AND PRESIDENT GREGORY MADISON RESIGNED.APPOINTED JODIE MORRISON AS INTERIM CHIEF EXECUTIVE OFFICER.REDUCED SIZE OF BOARD FROM EIGHT DIRECTORS TO SEVEN DIRECTORS.  Full Article

Keryx Biopharma Says Norwich Pharmaceuticals Agreed To Terminate Manufacturing Services Agreement
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Keryx Biopharmaceuticals Inc ::KERYX BIOPHARMACEUTICALS- ON DEC 20,CO,NORWICH PHARMACEUTICALS AGREED TO TERMINATE MANUFACTURING SERVICES AGREEMENT BETWEEN CO,NPI,DATED JAN 17, 2014‍​.KERYX BIOPHARMACEUTICALS SAYS ‍TERMINATION OF AGREEMENT EFFECTIVE AS OF DEC 31, 2017​ - SEC FILING.  Full Article

U.S. FDA approves Auryxia tablets as treatment for people with iron deficiency anemia and chronic kidney disease
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :U.S. FDA approves Auryxia® (ferric citrate) tablets as a treatment for people with iron deficiency anemia and chronic kidney disease, not on dialysis.  Full Article

Keryx Biopharmaceuticals Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Keryx Biopharmaceuticals Inc :Keryx Biopharmaceuticals announces third quarter 2017 financial results.Q3 loss per share $0.20.Q3 revenue $15 million versus I/B/E/S view $17.9 million.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Keryx Biopharmaceuticals Inc- ‍cash and cash equivalents as of Sept 30, 2017 totaled $114.0 million compared to $111.8 million as of Dec 31, 2016​.  Full Article